D-IBS

US FDA grants fast track status to Lexicon's LX1033
Pharmaceutical Business Review
Mon, 12/24/12 - 10:55 am
FDA
Lexicon Pharmaceuticals
LX1033
D-IBS
Tioga nabs $10M VC deal amid PhIII for bowel disorder drug
Fierce Biotech
Fri, 04/13/12 - 10:51 am
Tioga
venture capital
D-IBS
irritable bowel syndrome
Series B
asimadoline